Adib Chaus, MD
Interventional Cardiology · Park Ridge, ILNPI 1699169862
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (57.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 68.1% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $27,268 and has fallen 85.4% since, to $3,980 in 2025.
Across 198 payments — averaging $192.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- Edwards Lifesciences$5K
- Abbott$3K
- Boston Scientific$1K
- Philips North America LLC$624
- Abiomed$550
- plus $2K from 23 others
Across 8 payments — averaging $5365.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$31K
- Amgen$11K
- Ionis Pharmaceuticals, Inc.$1K
What the payments were for
- Grants$22,00058%
- Travel & lodging$7,58520%
- Food & beverage$8,26822%
- Education$1971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 47 | $25,926 |
| Edwards Lifesciences | 52 | $5,092 |
| Abbott | 20 | $2,852 |
| Boston Scientific | 26 | $1,213 |
| Philips North America LLC | 4 | $624 |
| Abiomed | 12 | $550 |
| Inari Medical, Inc. | 2 | $265 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $252 |
| Shockwave Medical, Inc | 2 | $225 |
| Chiesi USA, Inc. | 1 | $132 |
| Sanofi-aventis U.S. LLC | 1 | $115 |
| Cardiva Medical, Inc. | 5 | $104 |
| Novartis | 1 | $86 |
| Regeneron Healthcare Solutions, Inc. | 1 | $76 |
| ZOLL Circulation Inc | 2 | $67 |
| Biotronik Inc. | 3 | $65 |
| Teleflex LLC | 2 | $64 |
| Johnson & Johnson | 1 | $61 |
| Regeneron | 1 | $55 |
| Biosense Webster, Inc. | 1 | $44 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| AstraZeneca | 1 | $26 |
| Asahi Intecc USA, Inc. | 1 | $23 |
| Cook Medical LLC | 1 | $23 |
| Getinge USA Sales, LLC | 1 | $19 |
| Amgen | 1 | $19 |
| Recor Medical Inc | 1 | $15 |
| Gentuity, LLC | 1 | $15 |
| EKOS Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$2,275
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,655
- OMNILINK ELITE$1,466
- US Und$593
- MitraClip$526
- MitraClip System$274
- FlowTriever$223
- ClotTriever$223
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$155
- OptiCross 6$146
- AVVIGO Guidance System$141
- Perclose ProGlide suture mediated closure system$140
- KENGREAL$132
- EVOQUE$132
- Farapulse$124
- VIGILANT X4 CRT-D$121
- NO PRODUCT DISCUSSED$115
- WATCHMAN Access System$115
- Impella$109
- Watchman$103
How this compares
$38,050 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $112,146 |
| EntrestoSacubitril/Valsartan | 52 | $68,487 |
| JardianceEmpagliflozin | 21 | $32,078 |
| XareltoRivaroxaban | 20 | $31,330 |
| Repatha SureclickEvolocumab | 35 | $26,717 |
| FarxigaDapagliflozin Propanediol | 12 | $11,705 |
| Praluent PenAlirocumab | 22 | $11,261 |
| Metoprolol Succinate | 181 | $2,998 |
| Atorvastatin Calcium | 195 | $1,796 |
| Midodrine Hcl | 14 | $1,770 |
| Ezetimibe | 89 | $1,728 |
| Rosuvastatin Calcium | 136 | $1,583 |
| Losartan Potassium | 78 | $1,165 |
| Amlodipine Besylate | 129 | $1,127 |
| ClopidogrelClopidogrel Bisulfate | 65 | $771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $86 | $68,48752 claims |
| Johnson & JohnsonXarelto | $61 | $31,33020 claims |
| AstraZenecaFarxiga | $26 | $11,70512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Park Ridge
- Neal SawlaniPark Ridge$246K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.